Study finds Paxlovid treatment does not reduce risk of long

Research finds Paxlovid therapy doesn’t scale back threat of lengthy COVID

[ad_1]

Study finds paxlovid treatment does not reduce risk of long COVID
In all fashions, therapy with oral nirmatrelvir was not related to decrease odds of affected person reported Lengthy COVID signs with confidence intervals that cross 1, which means that therapy isn’t helpful in lowering the danger of Lengthy COVID. Mannequin 3, the prespecified main outcome, contains age, intercourse, and time since SARS-CoV-2 an infection, and the restricted cubic spline of the propensity rating. Mannequin 1 contains age, intercourse, and time since SARS-CoV-2 an infection. Mannequin 2 contains age, intercourse, time since SARS-CoV-2 an infection, race/ethnicity, previous medical historical past and substance use. Mannequin 4 is the propensity-adjusted model of Mannequin 2. Lastly, Mannequin 5 incorporates inverse chance of therapy weighting and age, intercourse, and time since SARS-CoV-2 an infection. Outcomes had been comparable in extra sensitivity analyses. CI, confidence interval. Credit score: Journal of Medical Virology (2024). DOI: 10.1002/jmv.29333

A workforce of researchers from UC San Francisco has discovered that Paxlovid (Nirmatrelvir-ritonavir) didn’t scale back the danger of creating lengthy COVID for vaccinated, non-hospitalized people throughout their first COVID-19 an infection. Additionally they discovered a better proportion of people with acute signs rebound and test-positivity than beforehand reported.

The research appears within the Journal of Medical Virology.

Paxlovid therapy for acute COVID-19 has been proven to be efficient for high-risk unvaccinated people. However the impact of the therapy on lengthy COVID threat, together with whether or not it protects vaccinated folks from getting lengthy COVID, has been much less clear.

The analysis workforce chosen a gaggle of vaccinated folks from the UCSF COVID-19 Citizen Science research who had reported their first optimistic check for COVID-19 between March and August of 2022 and who weren’t hospitalized.

A few of these members reported taking oral Paxlovid therapy through the acute section of their COVID-19 an infection, whereas others didn’t. In December of 2022, they had been invited to reply a follow-up survey with questions on lengthy COVID, COVID rebound signs, and the way lengthy they continued to check optimistic.

Researchers discovered the 2 teams had been comparable. About 16% of these handled with Paxlovid had lengthy COVID signs in comparison with 14% of those that weren’t handled with the treatment. Generally reported signs included fatigue, shortness of breath, confusion, headache, and altered style and scent.

Those that took Paxlovid after which went on to develop lengthy COVID reported as many lengthy COVID signs as those that weren’t handled with Paxlovid. A small share of individuals developed extreme long-term COVID, and people who had acquired Paxlovid had been simply as prone to have extreme Lengthy-term COVID signs as those that didn’t.

Amongst people who skilled symptomatic enchancment throughout Paxlovid therapy, 21% reported rebound signs. And amongst these with rebound signs, 10.8% reported a number of Lengthy COVID signs in comparison with 8.3% with out rebound signs. For members who repeated antigen testing after testing damaging and finishing therapy, 25.7% reported rebound check positivity. In complete, 26.1% reported rebound signs or check positivity.

“We discovered a better proportion with medical rebound than beforehand reported however didn’t establish an impact of post-treatment rebound on lengthy COVID signs,” mentioned research first writer Matthew Durstenfeld, MD, MAS, a heart specialist and UCSF assistant professor of Drugs.

“Our discovering that Paxlovid therapy throughout acute an infection isn’t related to decrease odds of lengthy COVID shocked us, however it’s per two different rigorously performed research discovering no distinction in post-COVID situations between 4 and 6 months after an infection.”

The authors be aware that the research could have been impacted by limitations arising from its observational nature with researchers counting on affected person self-reporting of therapy and Lengthy COVID signs.

Extra info:
Matthew Durstenfeld et al, Affiliation of Nirmatrelvir for Acute SARS-CoV-2 An infection with Subsequent Lengthy COVID Signs in an Observational Cohort Research, Journal of Medical Virology (2024). DOI: 10.1002/jmv.29333

Supplied by
College of California, San Francisco


Quotation:
Research finds Paxlovid therapy doesn’t scale back threat of lengthy COVID (2024, January 4)
retrieved 8 January 2024
from

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

Add a Comment

Your email address will not be published. Required fields are marked *